Perspectives Of Colorectal Cancer Screening And Early Clinical Diagnosis | 12958
ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Perspectives of Colorectal Cancer Screening and Early Clinical Diagnosis

International Conference on Epidemiology and Evolutionary Genetics

Shu Zheng

Accepted Abstracts: Epidemiol

DOI: 10.4172/2161-1165.S1.004

W ith the aging and growth of world population, high prevalence of unhealthy behaviors such as smoking and alcohol drinking, and increasing unhealthy food consumption and sedentary lifestyles including low physical activity and obesity/ overweight, colorectal cancer (CRC) has become a big burden on global health. Prevention and early diagnosis of CRC through mass screening is important and practical against CRC. Low compliance for current screening tests affects the effectiveness of CRC mass screening. An efficient screening protocol with high compliance is needed for CRC mass screening. Systematic searches were done through Medline and Cochrane Library databases. This review explored the current CRC mass screening protocols to find a more efficient and practical mass screening protocol and problems suitable for further research. Considering the current economic crisis and limited available resources, combination of high risk factor questionnaire and immunochemical fecal occult blood test approach as primary CRC mass screening can currently be used as a risk stratification tool to identify high-risk populations from the community, especially for medically and economically underserved areas/countries before a new better test comes. Using serum Pyruvate Kinase Isoenzyme M2 (M2-PK) as primary and colonoscopy as secondary screening test sounds more efficient with higher compliance than current CRC mass screening protocols. Recommendations for CRC mass screening are suggested for each risk population based on risk stratification. Serum M2- PK- may be developed as a promising CRC primary mass screening test. Sequential combination of serum biomarker such as M2-PK and colonoscopy can be a promising CRC mass screening protocol.
Zheng is MD and Professor of Oncologist in Zhejiang University Cancer Institute and was President of Zhejiang Medical University. Dr. Zhu obtained Ph.D. in Epidemiology from Johns Hopkins University Bloomberg School of Public Health, M.Sc. from Clemson University, and MD from Zhejiang University. Dr. Zhu has expertise in epidemiologic methods, application of epidemiologic methods in clinical medicine, public health and other health sciences including cancer and other chronic diseases, toxicology, food and nutrition, and molecular medicine. Especially, Dr. Zhu has unique expertise in translating basic research into animal/tissue research and into clinical and population research and interpreting clinical and population research results using biologic mechanisms from basic and animal/tissue research.